Jane Street Group LLC Decreases Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Jane Street Group LLC decreased its stake in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 47.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 136,935 shares of the company’s stock after selling 123,146 shares during the period. Jane Street Group LLC’s holdings in Atossa Therapeutics were worth $208,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. State Street Corp grew its position in shares of Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after buying an additional 69,180 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Atossa Therapeutics by 11.9% in the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company’s stock worth $1,846,000 after acquiring an additional 164,540 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Atossa Therapeutics by 3,160.5% in the second quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after acquiring an additional 399,041 shares during the last quarter. Rhumbline Advisers acquired a new position in Atossa Therapeutics during the 2nd quarter worth approximately $161,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Atossa Therapeutics in the 3rd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Trading Down 2.3 %

ATOS stock opened at $0.90 on Monday. The stock has a market cap of $113.69 million, a P/E ratio of -4.11 and a beta of 1.26. Atossa Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $2.31. The company’s 50 day moving average is $1.18 and its two-hundred day moving average is $1.30.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research report on Thursday, December 12th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.